Literature DB >> 31095926

Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update.

Sushma Jonna1, Deepa S Subramaniam1.   

Abstract

The understanding of genetic alterations that drive non-small cell lung cancer (NSCLC) is evolving. As many of these molecularly-defined subtypes are potentially actionable, new strategies in molecular diagnostics and targeted therapies in NSCLC to detect and treat them are being explored. At the International Association for Study of Lung Cancer 19th World Conference, several abstracts and oral presentations related to this topic. In this report, we discuss some of these updates.

Entities:  

Year:  2019        PMID: 31095926

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  70 in total

1.  Risk factor of brain metastases and its influence on patient prognosis after complete resection of non-small cell lung cancer.

Authors:  Jinlei Li
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Efficacy and safety of thoracoscopic resection for early-stage non-small cell lung cancer.

Authors:  Peng Cao; Jiaqi Yue; Shan Hu; Kangle Kong; Peng Han; Ziheng Yang; Yu Deng; Fan Li; Bo Zhao
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells.

Authors:  Jingjing Liu; Liming Cao; Yuanyuan Li; Pengbo Deng; Pinhua Pan; Chengping Hu; Huaping Yang
Journal:  Hum Cell       Date:  2022-08-25       Impact factor: 4.374

4.  Abiraterone suppresses irradiated lung cancer cells-induced angiogenic capacities of endothelial cells.

Authors:  Tingyan Ruan; Liping Jiang; Junying Xu; Juying Zhou
Journal:  J Bioenerg Biomembr       Date:  2021-04-05       Impact factor: 2.945

5.  LINC00961 functions as an anti-oncogene in non-small cell lung carcinoma by regulation of miR-3127.

Authors:  Yong-Gang Liu; Jia Li; Fang Nie; Gao-Wa Jin
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

6.  Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer.

Authors:  Ling Wang; Yue Dai; Fuliang Zhu; Zhimin Qiu; Yaqi Wang; Yinghui Hu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

7.  Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile.

Authors:  Sisi Deng; Xiaoli Lu; Zhi Zhang; Rui Meng; Mi Li; Shilin Xia
Journal:  J Cell Mol Med       Date:  2021-06-02       Impact factor: 5.310

8.  LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p.

Authors:  Lei Zhang; Baihong Chi; Jin Chai; Li Qin; Guangxin Zhang; Peiyan Hua; Chengyan Jin
Journal:  Mol Biotechnol       Date:  2021-06-11       Impact factor: 2.695

9.  Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975.

Authors:  Dongbo Zhou; Zhi Xia; Mingxuan Xie; Ying Gao; Qiao Yu; Baimei He
Journal:  Hum Cell       Date:  2021-07-09       Impact factor: 4.174

10.  Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.

Authors:  Yu-Jie Cui; Jia Liu; Miao-Miao Liu; Hong-Zhen Zhang
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.